Ajanta Pharma Limited Stock Target Price
| AJANTPHARM | 2,930 96.45 3.19% |
Ajanta Pharma Limited fundamentals help investors to digest information that contributes to Ajanta Pharma's financial success or failures. It also enables traders to predict the movement of Ajanta Stock. The fundamental analysis module provides a way to measure Ajanta Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ajanta Pharma stock.
Ajanta | Target Price |
Ajanta Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ajanta Pharma's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ajanta Pharma could also be used in its relative valuation, which is a method of valuing Ajanta Pharma by comparing valuation metrics of similar companies.Ajanta Pharma is currently under evaluation in target price category among its peers.
Ajanta Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 366.77 B | ||||
| Shares Outstanding | 124.91 M | ||||
| Shares Owned By Insiders | 66.47 % | ||||
| Shares Owned By Institutions | 22.04 % | ||||
| Price To Book | 10.18 X | ||||
| Price To Sales | 8.42 X | ||||
| Revenue | 42.09 B | ||||
| Gross Profit | 26.92 B | ||||
| EBITDA | 12.57 B | ||||
| Net Income | 8.16 B | ||||
| Total Debt | 352.8 M | ||||
| Book Value Per Share | 293.33 X | ||||
| Cash Flow From Operations | 7.85 B | ||||
| Earnings Per Share | 69.52 X | ||||
| Target Price | 2992.82 | ||||
| Number Of Employees | 8.07 K | ||||
| Beta | 0.1 | ||||
| Market Capitalization | 378.08 B | ||||
| Total Asset | 46.38 B | ||||
| Retained Earnings | 33.14 B | ||||
| Working Capital | 18.35 B | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 46.38 B | ||||
| Last Dividend Paid | 54.0 |
About Ajanta Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ajanta Pharma Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ajanta Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ajanta Pharma Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Ajanta Stock
Ajanta Pharma financial ratios help investors to determine whether Ajanta Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ajanta with respect to the benefits of owning Ajanta Pharma security.